Natera

Natera Equity

The The Equity of Natera (NTRA) as of Nov 22, 2026 is 1.71 B USD. In the previous year, The Equity was 1.20 B USD — a change of 43.25% (higher).

Equity

1.71 BUSD

YoY

43.25%

Last updated:

In 2025, Natera's equity was 1.71 B USD, a 43.25% increase from the 1.20 B USD equity in the previous year.

The Natera Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
32.16 M USD
Jan 1, 2019
278.71 M USD
Jan 1, 2020
486.24 M USD
Jan 1, 2021
653.30 M USD
Jan 1, 2022
705.74 M USD
Jan 1, 2023
765.33 M USD
Jan 1, 2024
1.20 B USD
Jan 1, 2025
1.71 B USD
The Natera Equity history
YEAREquityYoY
1.71 BUSD+43.25%
1.20 BUSD+56.20%
765.33 MUSD+8.44%
705.74 MUSD+8.03%
653.30 MUSD+34.36%
486.24 MUSD+74.46%
278.71 MUSD+766.58%
32.16 MUSD+26.54%
25.42 MUSD-76.13%
106.48 MUSD-42.37%
184.77 MUSD-207.84%
-171.34 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Natera Stock analysis

What does Natera do? Natera Inc. is an American company headquartered in San Carlos, California. It was founded in 2004 by Matthew Rabinowitz and has been listed on the NASDAQ under the ticker symbol "NTRA" since 2015. The company is a leading provider of diagnostic tests and analyses and specializes in genetic analysis and diagnostic technologies. Natera specializes in tests for various medical areas, particularly in oncology diagnostics. The company's vision is to improve the quality of life for millions of people worldwide by offering innovative diagnostic tests to detect diseases early and ensure optimal treatment. Natera offers a wide range of products tailored to the needs of consumers, physicians, and scientists. The company operates in three business areas: 1) Women's Health: Natera offers tests for women and couples to determine the risk of hereditary diseases. For example, the company offers a test that allows analysis of fetal DNA from the mother's blood, allowing detection of genetic abnormalities in the fetus before birth. Additionally, Natera offers the Panorama test, which provides tests for genetic anomalies in unborn babies that can be used to determine the risk for chromosomal abnormalities and genetic mutations. 2) Oncology: In the field of oncology, Natera offers a wide range of diagnostic tests targeting developments and trends in cancer research. The tests aim to enable accurate diagnosis and prognosis, as well as provide individualized treatment for each patient. The company offers tests that assess the current tumor growth and metastatic potential, enable determination of tumor burden in cells, and provide tests for specific mutations required for determining optimal treatment. 3) Genomic Analysis: In the field of genomic analysis, Natera offers a broad range of tests available to researchers and scientists. This includes genetic variants and biological mechanisms that cause diseases. The company is also committed to developing its tests through artificial intelligence (AI) and machine learning. The goal is to provide more accurate and faster results, improve clinical decisions, and advance research and development of new diagnostics. Conclusion: Natera is a leading company in the field of diagnostic tests and analyses in the field of genomic analysis. The company has a long history of research and development of innovative product solutions for the medical community. One important focus of the company is to improve women's health and be able to detect risks for genetic diseases early; the other focus is on oncology diagnostic tools to determine optimal treatment for cancer patients. The company is constantly striving to further develop its tests and integrate new research findings and technologies to support the medical science community. Natera is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Natera's Equity

Natera's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Natera's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Natera's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Natera's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Natera’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Natera stock

The Equity of Natera is 1.71 B USD in 2025.

The Equity of Natera changed from 1.20 B USD to 1.71 B USD, representing a 43.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Natera since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Natera historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Natera

All Key Metrics — Natera